OAN Staff Brooke Mallory
5:35 PM – Monday, August 10, 2026
President Donald Trump has signed an executive order (EO) restructuring the United States’ childhood immunization schedule, calling for a major overhaul of federal guidance to space out vaccines across multiple doctor visits.
Described by the White House as the “Gold Standard Childhood Vaccine Recommendations,” the order aims to shift away from long-standing federal guidelines by recommending that children receive individual immunizations during separate appointments rather than receiving multiple shots in a single visit.
Under the newly issued framework, the number of diseases targeted by universally recommended childhood vaccines is reduced from 18 down to 11, covering core illnesses such as measles, mumps, rubella, polio and whooping cough.
Other routinely administered vaccines — including those for COVID-19, influenza, hepatitis A and B, RSV, and meningococcal disease — have been shifted into a “shared clinical decision-making” tier reserved for “high-risk” children or optional consultation between parents and healthcare providers.
The directive also specifically advises breaking up the standard combined measles, mumps, and rubella (MMR) vaccine into three standalone, single-disease shots given over separate visits, according to the EO.
During the Oval Office signing ceremony, Trump cited rising autism diagnosis rates as a driving factor behind the policy shift, maintaining that the volume and timing of early childhood injections play a major role.
However, following the announcement, industry officials pointed out immediate hurdles to implementing the Trump administration’s plan. Standalone single-disease vaccines for measles, mumps, and rubella are not currently approved or commercially manufactured in the United States, as primary producers discontinued separate doses in 2009 in favor of the combined MMR shot.
Nonetheless, the Trump administration addresses this practical limitation by labeling the recommendation as a long-term directive rather than an immediate mandate.
- The EO: Specifically directs that the MMR vaccine be separated into three single-disease shots “once such products are domestically available.” The administration acknowledges that the standalone shots do not currently exist on the U.S. market, making the provision contingent on future manufacturing.
- HHS Directive for Research & Development: President Trump instructed Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and the HHS Task Force on Safer Childhood Vaccines to evaluate vaccine scheduling, research, and dosing options. Part of the administration’s policy direction relies on encouraging pharmaceutical manufacturers or federal researchers to eventually develop, test, and seek regulatory approval for standalone single-disease vaccines.
- Interim Status Quo: Since standalone doses are not approved or manufactured in the U.S. and federal court injunctions remain active, administration officials say that the order serves as a policy recommendation and presidential guidance for parents and doctors rather than an immediate change to what is available at the clinic counter today.
While federal guidance ultimately shapes national insurance coverage and public policy recommendations, mandatory school vaccination requirements still remain under the jurisdiction of individual state governments. The EO encourages U.S. states to revise their respective school entry mandates to reflect the Trump administration’s new guidelines.
Stay informed! Receive breaking news alerts directly to your inbox for free. Subscribe here. https://www.oann.com/alerts
What do YOU think? Click here to jump to the comments!
Sponsored Content Below
Be the first to comment